Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Dna-Seq Inc. is active in the Biotechnology & Pharmaceuticals technology area with a portfolio that currently includes 2 pending office actions. These actions are spread across 2 distinct examiners and 2 distinct art units, indicating technical variety in the company's current filings.
The busiest examiner for this portfolio is ANDERSON-FEARS, KEENAN NEIL, who is responsible for 1 pending office action. Because there are 2 pending office actions in total, the workload is divided among the 2 distinct examiners. This distribution across 2 distinct art units suggests that the company is pursuing multiple technical paths within the Biotechnology & Pharmaceuticals sector.
For a patent practitioner, this profile shows a more diversified prosecution strategy than a portfolio with 1 pending office action. The use of 2 distinct examiners and 2 distinct art units means the company's success is not tied to a single individual or unit, providing multiple opportunities for patent allowance. This diversification can be a strategic advantage in complex technology areas. The data reflects that 1 pending office action is handled by the busiest examiner while the remaining workload is managed by another examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON-FEARS, KEENAN NEIL | 1 | 15.4% | +37.5% |
| LIU, GUOZHEN | 1 | 48.1% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921477 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | ANDERSON-FEARS, KEENAN NEIL | — |
| 16866281 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | LIU, GUOZHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921477 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | ANDERSON-FEARS, KEENAN NEIL | — |
| 16866281 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | LIU, GUOZHEN | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921477 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | ANDERSON-FEARS, KEENAN NEIL | 1687 | §103 | Non-Final OA | — | Pending | Oct 26, 2022 |
| 16866281 | METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY | LIU, GUOZHEN | 1686 | §101DP | Final Rejection | — | Pending | May 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDna-Seq Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Keenan Neil Anderson-Fears has the most, with 1 of Dna-Seq Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
